摘要
目的探讨西酞普兰与氯米帕明治疗抑郁症的临床疗效及安全性。方法将68例抑郁症患者随机分为两组各34例,研究组口服西酞普兰治疗,对照组口服氯米帕明治疗,观察6w。于治疗前及治疗1w、2w、4w、6w末采用汉密顿抑郁量表和副反应量表评定临床疗效和不良反应。结果治疗6w末,研究组显效率73.5%、有效率85.3%;对照组分别为70.6%和82.4%,两组间比较差异无显著性(P均>0.05)。两组治疗1w末起汉密顿抑郁量表评分较治疗前均下降明显,研究组治疗1w、2w末较对照组下降显著(P<0.01),其他时点差异无显著性(P>0.05)。研究组治疗6w末副反应量表评分显著低于对照组(t=2.935,P<0.01),不良反应较轻微。结论西酞普兰治疗抑郁症疗效与氯米帕明相当,但起效较氯米帕明更快,安全性更高,依从性更好。
Objective To explore the efficacy and safety of citalopram vs. clomipramine in the treatment of patients with depression. Methods 68 depression patients were randomly divided into research group（n=34） orally took eitalopram and control group（n=34） elomipramine for 6 weeks. Clinical efficacy and adverse effects were assessed with the Hamilton Depression Rating Seale（HAMD） and the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 1st, 2nd,4th and 6th week treatment, respectively. Results At the end of the 6th week, excellence and effectiveness rates were respectively 73.5% and 85.35 in the research group and 70.6% and 82.4% in the control group, which had no significant differences（both P〉0.05）. Since the end of the 1st week, the HAMD score lowered very significantly in the research group and significantly in the control group compared with pretreatment; at the ends of the 1st and 2nd week, the HAMD score lowered more significantly in the research than in the control group（P〈0.01） and there was no significant difference in the other time-points （P〉0.05）. At the end of the 6th week, the TESS score was significantly lower in the research than in the control group（P〈0.01） and adverse effects of the former were mild. Conclusion Citalopram has equivalent efficacy to clomipramine but takes effects faster and has higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2008年第1期14-15,共2页
Journal of Clinical Psychosomatic Diseases
